New York State Common Retirement Fund Sells 11,822 Shares of Glaukos Co. (NYSE:GKOS)

New York State Common Retirement Fund lessened its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 381,288 shares of the medical instruments supplier's stock after selling 11,822 shares during the period. New York State Common Retirement Fund owned approximately 0.69% of Glaukos worth $57,170,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in GKOS. Values First Advisors Inc. bought a new stake in Glaukos in the 3rd quarter worth approximately $25,000. Asset Planning Inc bought a new stake in Glaukos in the 4th quarter worth approximately $90,000. Harvest Fund Management Co. Ltd grew its position in shares of Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock valued at $117,000 after acquiring an additional 860 shares during the period. KBC Group NV grew its position in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock valued at $188,000 after acquiring an additional 201 shares during the period. Finally, EWA LLC bought a new stake in shares of Glaukos during the 3rd quarter valued at $209,000. Institutional investors own 99.04% of the company's stock.

Glaukos Price Performance

GKOS stock traded down $31.33 during mid-day trading on Friday, hitting $126.03. The company had a trading volume of 4,139,906 shares, compared to its average volume of 515,602. The company has a market capitalization of $6.95 billion, a price-to-earnings ratio of -43.91 and a beta of 1.04. Glaukos Co. has a 12-month low of $83.90 and a 12-month high of $163.71. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average price of $152.75 and a 200 day moving average price of $139.41.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The company had revenue of $105.50 million during the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. On average, research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company's stock, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,744 shares of company stock worth $2,792,151 in the last 90 days. 6.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of recent research reports. Needham & Company LLC boosted their price objective on shares of Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research report on Friday. JPMorgan Chase & Co. boosted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Morgan Stanley downgraded shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price objective for the company. in a research report on Monday, December 2nd. BTIG Research boosted their price objective on shares of Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Finally, Stifel Nicolaus boosted their price objective on shares of Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research report on Tuesday, December 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.